<DOC>
	<DOCNO>NCT02836288</DOCNO>
	<brief_summary>The primary purpose study see safe give patient head neck cancer low dose FDA approve anesthetic drug ketamine time receive radiation , chemotherapy , and/or surgery cancer treatment treat depression effect . Researchers would also like see give ketamine time cancer treatment practical reasonably acceptable patient . Depression many negative consequence outcomes head neck cancer . It cause delayed treatment , increase hospital lengths stay , decrease treatment adherence , poor self-care , decrease quality life , even 3 year post treatment . The presence depression number one predictor incomplete treatment difficulty rehabilitation . Therefore , investigator would also like see feasible give patient ketamine routine cancer treatment treat depression negative effect cancer treatment outcome , also help anxiety , pain , quality life . The study also use placebo compare good and/or bad effect ketamine . A placebo active drug look ketamine , liquid take mouth . Ketamine approve U.S. Food Drug Administration ( FDA ) general anesthetic diagnostic surgical procedure combine general anesthetic agent . It also show reduce cancer pain . Ketamine consider experimental study approve FDA treatment depression .</brief_summary>
	<brief_title>Study Oral Ketamine Versus Placebo Treating Depression Patients Undergoing Treatment Head Neck Cancer</brief_title>
	<detailed_description>This prospective , single center , double blind , randomize , two-arm feasibility study oral ketamine versus placebo treatment depression depress patient head neck cancer undergo curative intent cancer therapy . Approximately 20 patient head neck cancer undergo cancer therapy randomize 1:1 receive study treatment one follow regimen : Arm A : nightly oral administration 1.0 mg/kg ketamine Arm B : nightly oral administration placebo Consenting patient undergo screening procedure , eligible , baseline interview brief questionnaires regard depression , mental emotional health , quality life assessment . Study treatment administer 12 week unless patient experience unacceptable toxicity , exhibit moderate severe depressive symptom , withdraws consent . Patients placebo treatment arm eligible cross ketamine arm evidence depression remove study treat standard medical management depression . Patients ask complete psychosocial measurement every two week study treatment monthly five-month follow-up period .</detailed_description>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Ketamine</mesh_term>
	<criteria>Ability understand willingness sign write informed consent . Stage IIIV epidermoid cancer head neck . Subject receive within four week receive curative intent cancer treatment radiation plus/minus chemotherapy Age ≥ 18 year . Has moderate severe depression accord Quick Inventory Depressive SymptomatologySelf Rated 16 ( QIDSSR16 ) score ≥ 11 AND Hospital Anxiety Depression Scale ( HADS ) Depression subscale score ≥ 8 . Documented adequate liver function within screen period define : ALT &lt; 5 X institutional upper limit normal ( ULN ) AST &lt; 5 X institutional ULN Total bilirubin &lt; 5 X institutional ULN Both men woman race ethnic group eligible trial . Use antidepressant permit dose least 12 week prior study entry still meet inclusion # 5 . Women childbearing potential men partner childbearing potential must agree use adequate contraception ( hormonal barrier method birth control ; abstinence ) prior study entry duration study participation . Should woman become pregnant suspect pregnant participating study , inform treat study physician immediately . Urine pregnancy test do throughout trial . Must read understand English fluently . Receiving another investigational agent clinical trial prohibits participation study investigational agent . Meets MINI International Neuropsychiatric Interview ( MINI Plus ) ,88 criterion diagnosis schizophrenia , bipolar illness , delirium psychosis . Has high Suicidal Risk Assessment ( SRA ) score ≥ 10 . Use monoamine oxidase inhibitor within 14 day study entry . Diagnosed melanoma lymphoma cancer head neck . History allergic reaction hypersensitivity ketamine . Documented history severe cardiac insufficiency ( NYHA III IV ) , uncontrolled and/or unstable cardiac coronary artery disease . Documented history significant tachyarrhythmia , severe angina , myocardial ischemia Documented history poorly control hypertension ( Systolic Blood Pressure &gt; 180 mmHG Diastolic Blood Pressure &gt; 100 mmHG ) , without antihypertensive . If woman become pregnant nursing time treatment period , exclude study . Score ≥ 8 WHO Alcohol Use Disorders Identification Test ( AUDIT )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Ketamine</keyword>
	<keyword>Treatment Depression</keyword>
</DOC>